Medicines for the treatment of 2019-novel coronavirus 2019-nCoV infections are urgently needed. However drug screening using live 2019-nCoV requires high-level biosafety facilities which imposes an obstacle for those institutions without such facilities or 2019-nCoV. This study aims to repurpose the clinically approved drugs for the treatment of coronavirus disease 2019 COVID-19 in a 2019-nCoV-related coronavirus model. Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus-related coronavirus model.